16/04/2014 03:25:12 Free Membership Login

Xenoport News (NASDAQ:XNPT)

DateTimeSource
Headline
02/24/201410:00AMBWXenoPort to Present at the Cowen and Company 34th Annual Health Care Conference
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Cowen and Company 34th Annual Health Care Conference. The live presentation will occur at 7:40 a.m. Pacific Time (10:40 a.m. Eastern Time) on Wednesday, March 5, 2014. A replay of the presentation... More...>>
02/20/20144:05PMBWXenoPort Reports Fourth Quarter and Year-End 2013 Financial Results
XenoPort, Inc. (Nasdaq:XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that... More...>>
02/18/20141:06PMBWXenoPort to Present at the RBC Capital Markets’ Global Healthcare Conference
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the RBC Capital Markets’ Global Healthcare Conference. The live presentation will occur at 11:35 a.m. Pacific Time (2:35 p.m. Eastern Time) on Tuesday, February 25, 2014. A replay of the presentation... More...>>
02/13/20148:30AMBWRLS/WED Survey of Patients’ Spouses and Partners Reveals Their Concern of Disease-Related Burdens
-- WED Foundation and XenoPort Announce New Results from the “Patient Odyssey” Survey -- The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq:XNPT) announced today the second phase of results from the “Patient Odyssey” survey, which reveals how Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED... More...>>
02/12/20148:48PMBWXenoPort to Release Fourth Quarter and Year-End Financial Results on February 20, 2014
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its fourth quarter financial results on February 20, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event. To... More...>>
01/29/20148:30AMBWXenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
XenoPort, Inc. (Nasdaq:XNPT) announced today that Richard Kim, M.D., has been appointed senior vice president, clinical development and medical affairs, and chief medical officer. Dr. Kim joined XenoPort in July 2013 as vice president of medical affairs, supporting XenoPort’s launch of HORIZANT® (gabapentin enacarbil... More...>>
01/23/201411:00PMBWXenoPort Announces Pricing of Public Offering of Common Stock
XenoPort, Inc. (NASDAQ: XNPT) announced today the pricing of an underwritten registered public offering of 12,000,000 shares of its common stock at a price to the public of $6.00 per share. The size of the offering was increased from the 10,000,000 shares previously announced. XenoPort has also granted to the underwriters... More...>>
01/21/20146:00AMBWXenoPort Announces Proposed Public Offering of Common Stock
XenoPort, Inc. (Nasdaq: XNPT) announced today that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering. XenoPort also intends to grant the underwriters a 30-day option to purchase up to a maximum of 1,500,000 additional shares of... More...>>
01/16/20146:50PMZACKSPipeline Update from XenoPort - Analyst Blog
Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully... More...>>
01/12/20141:00PMBWXenoPort Provides Updates on XP23829 Development and HORIZANT Performance Highlights
XenoPort (NASDAQ:XNPT) today reported an update on XP23289 development, including feedback from the U.S. Food and Drug Administration (FDA) on the potential development plans, and XenoPort’s progress on commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets. XenoPort reported today that it received... More...>>
12/16/201311:40AMPRNUSClinton Group Calls on Xenoport to Hold Annual Elections for All Directors
Clinton Group Calls on Xenoport to Hold Annual Elections for All Directors PR Newswire NEW YORK, Dec. 16, 2013 NEW YORK, Dec. 16, 2013 /PRNewswire/ -- Clinton Group, Inc. ("Clinton Group"), one of the largest owners of Xenoport, Inc. (NASDAQ: XNPT) ("Xenoport"), sent a letter to the Lead Director of Xenoport, Dr. John... More...>>
11/15/20137:10AMDJNAQR Capital Management 3Q 13F: Largest Purchases -2-
TAKE TWO INTERACTIVE SOFTWARE $4,686,952 257,950 212,607 POLYCOM INC COM $29,382,237 2,690,681 206,953 BLACKROCK CREDIT ALLOCATION IN $8,777,394 673,113 205,488 ABERCROMBIE & FITCH CO CL A $19,263,988 544,642 202,583 EMERALD OIL INC COM $1,452,380 202,000 202,000 IMMERSION CORP COM $3,106,884 235,370 200,700 PPL CORP... More...>>
11/15/20137:10AMDJNAQR Capital Management 3Q 13F: Largest Sales
DJ CFA SOURCE: SEC 13F-HR FILER: AQR Capital Management LLC QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest sales of AQR Capital Management LLC are listed below, ordered by the number of shares sold during the three months ended Sep. 30. Company Name Value Holdings Change PFIZER INC COM $198,195,060... More...>>
11/13/20138:30AMBWWED Foundation and XenoPort Announce Preliminary Results from the “Patient Odyssey” Survey
-- Survey Reveals Significant Long-Term Challenges in RLS/WED Management -- The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq: XNPT) announced today the preliminary results from the “Patient Odyssey” survey, which reveal the challenges experienced by patients with Restless Legs Syndrome/Willis-Ekbom... More...>>
11/07/20134:05PMBWXenoPort Reports Third Quarter Financial Results
Announces Encouraging Pharmacodynamic Data from Previous XP23829 Phase 1 Trial XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2013. Revenues for the third quarter were $2.5 million, compared to $0.4 million for the same period in 2012. Net loss... More...>>
11/06/201310:00AMBWXenoPort to Present at the Credit Suisse Healthcare Conference
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2013 Credit Suisse Healthcare Conference. The live presentation will occur at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on Wednesday, November 13, 2013. A replay of the presentation will also... More...>>
10/30/20135:00PMBWXenoPort to Release Third Quarter Financial Results on November 7
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its third quarter financial results on November 7, 2013 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results, general business updates and... More...>>
10/15/20139:36PMBWXenoPort Issues Statement
XenoPort, Inc. (NASDAQ: XNPT) today issued the following statement: “The XenoPort Board of Directors has received the letter sent today from the Clinton Group. The XenoPort Board and management team appreciate stockholder input regarding the company, and we will continue to review all aspects of the company’s business... More...>>
10/15/20139:36AMDJNU.S. Hot Stocks Futures: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Tuesday's session are Citigroup Inc. (C), Coca-Cola Co. (KO) and Johnson & Johnson (JNJ). Citigroup posted disappointing results for its third quarter as the bank, like its peers, was hit by a slump in fixed-income trading and mortgage-banking revenue. Both... More...>>
10/15/20138:13AMPRNUSClinton Group Calls on Xenoport to Hire a New CEO and Focus on Promising Drug in its Pipeline
Clinton Group Calls on Xenoport to Hire a New CEO and Focus on Promising Drug in its Pipeline PR Newswire NEW YORK, Oct. 15, 2013 NEW YORK, Oct. 15, 2013 /PRNewswire/ -- Clinton Group, Inc. ("Clinton Group"), one of the largest owners of Xenoport, Inc. (NASDAQ: XNPT) ("Xenoport"), sent a letter to the Chief Executive... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq xnpt140416 03:25